Exudative AMD subtypes and eligibility for treatment with ranibizumab

Eye

Volumn 24, Issue 7, 2010, Pages 1247-1251

  George, S ^a   Cooke, C ^a   Chakravarthy, U ^b  

^a ROYAL GROUP OF HOSPITALS   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

age related macular degeneration; analysis; anti VEGF; choroidal neovascular membrane; eligibility; fluorescein angiogram

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR FIBROSIS; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

EID: 77954726273     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.301     Document Type: Article

References (17)

1. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R et al. The natural history and prognosis of age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008; 115: 116-126.
2. Chakravarthy U, Soubrane G, Gandello F, Chong V, Creuzot-Garcher C, Dimitrakos SA et al. Evolving European Guidance on the medical management of neovascular age-related macular degeneration. Br J Ophthalmol 2006; 90: 1188-1196.
3. Photodynamic Therapy of Subfoveal Choroidal Neovascularisationin Age-Related Macular Degeneration With Verteporfin. One-Year Results of 2 Randomised Clinical Trials TAP - Report 1. Arch Ophthalmol 1999; 117: 1329-1345.
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431.
5. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-1444.
6. Verteporfin in Photodynamic (VIP) Therapy Group. Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration - Two year Results of a Randomised Clinical Trial Including Lesions With Occult With No Classic Choroidal Neovascularistion - Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001; 131: 541-560.
7. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley Jr MA. Pharmacogenetics of complement factor H (Y402H) treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009; 93: 610-613.
8. NICE. Macular degeneration (age-related) - photodynamic therapy. The Clinical effectiveness and cost effectiveness of photodynamic therapy for age-related macular degenration. http://guidance.nice.org.uk/TA68.
9. NICE. Macular degeneration (age-related) - ranibizumab and pegaptanib. http://guidance.nice.org.uk/TA155.
10. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with vertepofin therapy and its potential impact on retinal practices. Retina 2000; 20: 325-330.
11. Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic factors at the early stage of exudative age related macular degeneration. Br J Ophthalmol 2002; 86: 663-669.
12. Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 2004; 111(2): 250-255. (Pubitemid 38183223)
13. Cohen SY, Creuzot-Garcher C, Darmon J, Desmettre T, Korobelnik JF, Levrat F et al. Types of choroidal neovascularisation (CNV) in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol 2007; 91: 1173-1176.
14. Viola F, Massacesi A, Orzalesi N, Ratiglia R, Staurenghi G. Retinal angiomatous proliferation: natural history and progression of visual loss. Retina 2009; 29: 732-739.
15. Gharbiya M, Allievi F, Recupero V, Martini D, Mazzeo L, Gabrielli CB. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-monht results. Retina 2009; 29: 740-749.
16. Konstantinidis L, Mameletzi E, Mantel I, Pouranaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis(R) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 2009; 247(9): 1165-1171.
17. Rouvas AA, Papakostas TD, Vavvas D, Vergados I, Moschos MM, Kotsolis A et al. Intravtireal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina 2009; 29: 536-544.